Showing results (141-150 of 205) with videos related to

Sort By:
Pageof 21
Hematology (Amsterdam, Netherlands)|October 7, 2025
Expert consensus definition of treatment intolerance in chronic myeloid leukemia in chronic phaseEhab Atallah, Michael S Broder, Onyee Chan, et al.
JAMA Network Open|December 18, 2023
Estimated Savings After Stopping Tyrosine Kinase Inhibitor Treatment Among Patients With Chronic Myeloid LeukemiaAaron N Winn, Ehab Atallah, Jorge Cortes, et al.
Leukemia|March 5, 2024
5G2 mutant mice model loss of a commonly deleted segment of chromosome 7q22 in myeloid malignanciesJasmine C Wong, Kelley M Weinfurtner, Tamara Westover, et al.
Cancer Research|January 5, 2011
Dose-dependent effects of focal fractionated irradiation on secondary malignant neoplasms in Nf1 mutant miceJean L Nakamura, Connie Phong, Emile Pinarbasi, et al.
Blood|November 2, 2014
Preclinical efficacy of MEK inhibition in Nras-mutant AMLMichael R Burgess, Eugene Hwang, Ari J Firestone, et al.
The New England Journal of Medicine|June 8, 2010
Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemiaHagop Kantarjian, Neil P Shah, Andreas Hochhaus, et al.
The New England Journal of Medicine|November 30, 2012
Ponatinib in refractory Philadelphia chromosome-positive leukemiasJorge E Cortes, Hagop Kantarjian, Neil P Shah, et al.
Blood|March 18, 2010
Use of chromosome engineering to model a segmental deletion of chromosome band 7q22 found in myeloid malignanciesJasmine C Y Wong, Yan Zhang, Kenneth H Lieuw, et al.
Blood|November 9, 2006
Beta common receptor inactivation attenuates myeloproliferative disease in Nf1 mutant miceAndrew Kim, Kelly Morgan, Diane E Hasz, et al.
Leukemia|January 29, 2024
Dose modification dynamics of ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) from the PACE and OPTIC trialsElias Jabbour, Jane Apperley, Jorge Cortes, et al.
Pageof 21